Blog
RSS FeedPosted by Michael Wonder on 29 May 2024
Zanubrutinib in combination with obinutuzumab for the treatment of patients with relapsed or refractory B-cell follicular lymphoma after two or more treatments
28 May 2024 - NICE is unable to make a recommendation on the use of zanubrutinib (Brukinsa) in combination with obinutuzumab ...
Posted by Michael Wonder on 29 May 2024
Trastuzumab deruxtecan for the treatment of patients with advanced HER2 mutation positive non-small-cell lung cancer after platinum-based chemotherapy
29 May 2024 - NICE is unable to make a recommendation on the use of trastuzumab deruxtecan (Enhertu) for the treatment ...
Posted by Michael Wonder on 24 May 2024
NICE and NHS England announce plan to enable innovative tech to be adopted quicker
23 May 2024 - NHS patients in England will benefit from faster access to the most innovative and cutting-edge medical technologies ...
Posted by Michael Wonder on 22 May 2024
Sirolimus for the treatment of patients with facial angiofibroma caused by tuberous sclerosis complex
22 May 2024 - NICE is unable to make a recommendation on the use of sirolimus (Hyftor) for the treatment of ...
Posted by Michael Wonder on 17 May 2024
Efanesoctocog alfa for the treatment and prevention of bleeding episodes in patients with haemophilia A
17 May 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 16 May 2024
Tisagenlecleucel for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukaemia
15 May 2024 - NICE has published final evidence-based recommendations on the use of tisagenlecleucel (Kymriah) for the treatment of ...
Posted by Michael Wonder on 16 May 2024
Acceptability of using real world data to estimate relative treatment effects in health technology assessments: barriers and future steps
15 May 2024 - Evidence about the comparative effects of new treatments is typically collected in randomised controlled trials (RCTs). In ...
Posted by Michael Wonder on 16 May 2024
Selinexor in combination with bortezomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (final guidance)
15 May 2024 - NICE has published final evidence-based recommendations on the use of selinexor (Nexpovio) in combination with bortezomib ...
Posted by Michael Wonder on 15 May 2024
Atogepant monohydrate for the prevention of migraine
15 May 2024 - NICE has published final evidence-based recommendations on atogepant monohydrate (Aquipta) for preventing migraine in adults. ...
Posted by Michael Wonder on 14 May 2024
Outlook Therapeutics announces UK submission of marketing authorisation application for ONS-5010 as a treatment for wet AMD
13 May 2024 - Outlook Therapeutics today announced the submission of its marketing authorisation application to the Medicines and Healthcare ...
Posted by Michael Wonder on 13 May 2024
First ever life-saving treatment for rare heart condition available on the NHS
13 May 2024 - NHS patients with a life-threatening heart condition are set to benefit from a cutting-edge new medicine ...
Posted by Michael Wonder on 13 May 2024
Remdesivir and the combination of tixagevimab and cilgavimab for the treatment of patients with COVID-19 disease (final guidance)
8 May 2024 - NICE has published final evidence-based recommendations on the use of remdesivir (Veklury) and tixagevimab and cilgavimab ...
Posted by Michael Wonder on 10 May 2024
SN Bioscience receives FDA fast track designation for small cell lung cancer
9 May 2024 - SN Bioscience announced on 7 May that the FDA has granted fast track designation for small cell ...
Posted by Michael Wonder on 10 May 2024
Tests could lead to fewer people having unnecessary chemotherapy after surgery for early breast cancer
10 May 2024 - More people with early breast cancer could be spared chemotherapy and therefore avoid the side effects associated ...
Posted by Michael Wonder on 08 May 2024
Selinexor with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma after 4 or more treatments
8 May 2024 - NICE has published evidence-based recommendations on the use of selinexor (Nexpovio) in combination with dexamethasone for ...